Alzheimer's Disease Peripheral Immune Multi-Omics Research and Clinical Validation

A 9.5 MB research document by Shi Lv, last updated in April 2026, details a multi-omics study of Alzheimer's disease. The work integrates GWAS meta-analysis data from 894,710 individuals with transcriptomic, epigenetic, and clinical data from the ADNI and AddNeuroMed cohorts. It identifies and validates peripheral immune causal genes like PTK2B and PLEKHA1, linking them to cognitive decline and disease progression.

Use Cases

• Prioritizing causal genes for Alzheimer's disease based on integrated GWAS and multi-tissue eQTL data.
• Validating gene expression biomarkers for disease progression using clinical cohort data like MMSE scores and CSF tau levels.
• Investigating epigenetic regulation in Alzheimer's disease based on identified methylation probes like cg19863426.
• Analyzing immune cell profile associations with gene expression from peripheral blood transcriptomes.

Strengths

• The underlying GWAS meta-analysis is based on a large sample size of 894,710 individuals.
• Clinical validation leverages multi-dimensional data from the ADNI cohort, including cognitive measures, CSF biomarkers, and plasma proteomics.
• Findings are independently replicated in the AddNeuroMed cohort, with specific statistical results provided (e.g., FDR P = 3.56 × 10⁻⁴).

Limitations

• The dataset is a DOCX document; the underlying raw data files, column definitions, and row counts are unavailable.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

Author Shi Lv, published on figshare.

Collection Method

Generated through integrated analysis of public GWAS data, multi-omics Mendelian randomization, single-cell transcriptomics, and validation in clinical cohorts (ADNI, AddNeuroMed).

Time Range

The study likely reflects data available up to its publication date in 2026.

Freshness

Last updated 2026-04-13 05:45:57; freshness should be verified.

Geography

Cohorts like ADNI and AddNeuroMed suggest a multi-national, likely Western, participant base.